$LH

Hawaii joins multistate settlement over Labcorp data breach

Hawaii joined a 44-state settlement with Labcorp over a 2019 data breach at its debt collector, American Medical Collection Agency, exposing 27.5 million people's data, including 17,347 Hawaiians. Labcorp will pay $2.2 million to states, including $17,628 to Hawaii, and improve security practices. A separate $35 million class-action settlement was also agreed.

Original reporting
Published Sep 30, 2026, 7:48 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 9:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Hawaii joins multistate settlement over Labcorp data breach — source image
Decision brief

The 30-second read

$LHBearishLow
01

Why it matters

The settlement adds a modest expense and may prompt tighter vendor oversight, but the financial hit is small relative to Labcorp's earnings.

02

Market read

A new legal settlement for Labcorp with limited financial impact but possible reputational and compliance implications.

03

What to watch

Potential future regulatory scrutiny and the precedent for other healthcare data‑breach settlements.

Relevance 5/10Novelty 5/10Timing: today

Background

Labcorp faced a massive 2019 breach affecting millions; this settlement resolves part of the fallout.

Company-level read

Ticker impact

$LHBearishHigh confidence
Context

Labcorp disclosed a new multistate settlement over the 2019 data breach, agreeing to pay $2.2 million total and $17,628 to Hawaii.

Expected impact

likely slight downward pressure as investors price in the settlement cost and compliance obligations

Evidence & confidence

The disclosed payment is a new liability; while the amount is small relative to Labcorp's size, settlements can prompt short‑term sell‑offs and heightened scrutiny of data‑security practices.

Market effects

May increase compliance focus across the healthcare diagnostics sector.

Minimal impact on Hawaii markets; primarily a corporate‑specific event.

Limited; the story is unlikely to affect broader market indices.

Counterpoint

The settlement cost is negligible for Labcorp's balance sheet and could be seen as a positive step toward stronger data security, potentially supporting the stock.

Key entities

  • Labcorp

    US‑listed diagnostics company (ticker LH) settling data‑breach claims.

  • American Medical Collection Agency

    Debt collector whose breach exposed Labcorp patient data.

Related articles

$LHMed

Why Labcorp Holdings Stock Dropped Today

Labcorp Holdings (LH) stock fell 3.3% after CMS announced plans to cut lab reimbursement rates by up to 15% starting in 2027. CMS payments accounted for 8% of Labcorp's 2025 revenue, according to its SEC filing. The company warned that reduced rates could materially impact its revenue and profitability.

$BABAMed

Stocks making the biggest moves premarket: Alibaba, Quest Diagnostics, On Holding, GameStop & more

Alibaba shares rose 3% after its CEO announced plans for 20+ gigawatts of data centers by 2032 and launched a new chip. Quest Diagnostics and Labcorp fell 5% each due to Medicare payment adjustments. Vicor gained 9% on strong Q3 guidance. On Holding jumped 6% after setting new financial targets and a $1B share buyback plan. GameStop rose 3.5% after its CEO bought 1.2M shares.

$DGXMed

Premarket movers: Quest, Labcorp hit by CMS cuts

U.S. stock index futures steadied on Tuesday. Quest Diagnostics (DGX) fell 6.9% and Labcorp (LH) dropped 4.5% after CMS proposed cuts to lab reimbursements. On Holding (ONON) rose 6.4% on a $1B share buyback plan. Vicor (VICR) surged 9.9% after raising Q3 revenue outlook. Endava (DAVA) fell 12% due to CFO investigation. GameStop (GME) gained 3.5% after CEO bought shares. AnaptysBio (ANAB) rose 3.8% on better-than-expected revenue.

$LHMedAI 8/10

Why is Labcorp stock sliding today?

Labcorp (LH) stock fell 3.4% after-hours to $310 following CMS's proposal to cut Medicare lab reimbursements by up to 15% annually starting 2027. CMS claims this corrects overpayments, potentially saving $1B yearly. Truist raised its price target to $365 but kept a Buy rating. Quest Diagnostics faces similar headwinds. The selloff was sector-specific, with broader markets flat.